Mitomycin pyelocalyceal (Jelmyto)
Jump to navigation
Jump to search
Mechanism of action
Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. Formulated for pyelocalyceal infusion.
Diseases for which it is used
History of changes in FDA indication
- 2020-04-15: Approved for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). (Based on OLYMPUS)
Also known as
- Brand name: Jelmyto